Piper Sandler Reiterates Overweight Rating on Moderna (MRNA)
June 6, 2024 7:51 AM
Piper Sandler analyst Edward Tenthoff reiterated an Overweight rating and $214.00 price target on Moderna (NASDAQ: MRNA).The analyst commented, "VRBPAC ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
